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Although it was not known at the time, the chemokine field started with the identification of a
protein byHeparin Sepharose affinity chromatography, platelet factor 4 (PF4) (1) now called CXCL4
in the systemic nomenclature introduced in 2000. As with many pathways in scientific research, our
entry into the field of chemokines and glycosaminoglycans (GAGs) was a series of fortuitous co-
incidences. Christine Power, working on the chemokine project in the Glaxo Institute of Molecular
Biology (GIMB) under the leadership of Tim Wells, had hired a postdoctoral scientist, Arlene
Hoogewerf to clonemurine CCR4, and to generate the KOmouse. Arlene had previously studied the
role of proteoglycans in regulating the function of othermolecules and had also previously published
a paper on the enzymatic activity of CTAP-III, and NAP-2, truncated forms of platelet basic
protein/CXCL7, to degrade heparin. Since our group was currently working on these chemokines
derived from the β-thromboglobulin precursor, and moreover we were all biochemists, our interest
was piqued by the relationship between chemokines and GAGs. This interest was of course inspired
by the paper recently published by Antal Rot demonstrating the evidence for haptotaxis as opposed
to chemotaxis (2), earning him the title of Godfather of Chemokine–GAG biology. Arlene then
followed a dual Post-doc pathway, partially hijacked by Tim to collaborate with him and his Ph.D.
student, Gaby Kuschert (now Gaby Campanella) to lay much of the biochemical groundwork
of chemokine–GAG interactions, and also fulfilling her goal of creating the CCR4 /  mouse.
They were able to show that chemokines demonstrated selectivity in their interaction with GAGs,
beyond the obvious electrostatic interactions between basic and acidic molecules, and importantly
made the observation that this interaction could trigger oligomerization of chemokines (3, 4). In
addition, theywere able to define the pharmacophore responsible forGAGbinding of the chemokine
IL-8/CXCL8 (5).
My lab became more directly involved in this research direction through the serendipitous
encounter of a Ph.D. student, Sarah Fritchley, working in Simi Ali’s lab in Newcastle, UK, who was
interested in expressing the putative GAG binding mutant of RANTES/CCL5 in E. coli, but who did
not have a viable expression system. Sarah spent a couple of months in the lab under the tuition of
our expert chemokine protein chemist, Fred Borlat, successfully producing the 40’s mutant, as we
colloquially called it. We published it in JBC with its correct biochemical nomenclature, 44AANA47-
RANTES (6). Perhaps an omen as to the importance of thismutant for us was that it was an exception
among most papers we had submitted as it was accepted overnight!
We were heavily involved in screening for chemokine receptor antagonists at this time, and
Marie Kosco-Vilbois had set up a simple cell recruitment assay to test putative inhibitors in vivo
– chemokine-induced peritoneal recruitment in mice. Therefore, to investigate the effect of the
abrogation of GAG binding in vivo, we asked her technician, Suzanne Herren, to test it for us. Being
very rigorous, and accustomed to testing compounds for their ability to inhibit chemokine induced
recruitment, in this instance RANTES, Suzanne tested it both for its agonist and antagonist activity.
I will never forget my amazement in seeing that the mutant was not only unable to recruit cells but
actually inhibited the recruitment induced by RANTES.
Again serendipity stepped in. I gave a talk at a BALR meeting in the UK, and after dinner at the
speaker’s table, joined the youngsters at the adjacent table for a post-prandial “relaxation”: : : (which
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would never happen in this day and age). There Imet Zoë Johnson,
whom I learned the next day, was toying with the idea of doing a
Ph.D., after having worked for a few years as an in vivo pharma-
cology laboratory assistant in in vivo pharmacology in industry.
Since I was responsible for the Student program at the Institute,
now the Serono Pharmaceutical Research Institute, she emailed
me soon after expressing her interest. Tim was by now Director
of the Institute, but had kept his interest in the chemokine project
close to his heart, and having the flair and ability to make quick
opportunistic decisions, immediately approved her appointment
to investigate this phenomenon further.
We then embarked on a marvelous and exciting 3 years
of research during Zoë’s thesis as the importance of the
chemokine–GAG interaction unveiled itself. This period was also
the beginning of my collaboration with Tracy Handel, one of the
most enjoyable and mutually fruitful collaborations between two
laboratories that I have had the pleasure to be part of, where we
shared everything without any trace of competiveness, leading to
several “duo” presentations of our joint discoveries at chemokine
meetings. The result of these 3 years, during which we had access
to other GAG binding mutants, notably those of MCP-1/CCL2
produced by Tracy’s lab in Berkeley, CA, USA, and that ofMIB-1β
fromPatti Liwang in Texas, was the demonstration that the immo-
bilization of chemokines on GAGs was essential for their in vivo
activity, and that moreover, certain chemokines needed to form
oligomers in order to exert their property of cellular recruitment
in vivo (7). The inter-relationship between these two properties
was shown by the failure to include another chemokine–GAG
mutant, that of murine MIP-1α, sent to us by Gerry Graham in
Glasgow. He included of course the WT control, which in our
hands was inactive in recruiting cells in vivo, despite his assurance
that it was fully active in vitro, so we saw no use in testing his GAG
binding mutant in our in in vivo assay. What he neglected to tell
us was that in line with the work carried out by Lloyd Czapeklski
at British Biotech some years previously the WT chemokine had
been mutated to no longer oligomerize – obviously an obligate
monomer that was inactive in vivo, in accordance with our results
with the three obligate monomers described above!
We then exploited the inter-relationship of GAG binding and
oligomerization using our RANTES mutant, now commonly
called 004, in our lab, an abbreviation of its company nomencla-
ture used for all biologicals, AS900004, and AANA-RANTES to
our collaborators, as a very effective anti-inflammatory tool (8–
10). However, the fact that it retained agonist activity precluded
its development as a biological therapeutic. However, we felt that
we were on the right path to discovering a novel set of molecules
that would interfere with the chemokine–GAG interaction and
would give us a superior niche to differentiate from our competi-
tors who were all targeting the chemokine:receptor interaction.
To achieve this, we used two approaches. The first lead by our
talented head of chemistry, Matthias Schwarz, was to carry out
an approach coined “SAR by NMR” to identify protein binders.
Our target protein RANTES/CCL5 had the advantage that (a)
it was small and therefore amenable to NMR technology, and
(b) its three dimensional structure in complex with a GAG – a
disaccharide – had been solved by our X-ray crystallographer,
Jeffrey Shaw (11). The aim was to screen a small library of about
200 sulfated compounds by NMR to identify RANTES/CCL5
binders. The first screen yielded a hit, which prevented bind-
ing to heparin, and inhibited RANTES-induced peritoneal cell
recruitment, despite only having micromolar affinity. The aim
was to then identify a second molecule in a second round of
screening, this time in the presence of the first compound, and
then using the data obtained from the structures of the complexes
solved by Jeff, to design a linker to form a dimer, which would
have considerably higher affinity. The screening and structural
biology arms worked beautifully, and the dimer was synthesized
by the chemists – but the product no longer inhibited cell recruit-
ment in vivo – and much to our chagrin and despair, it even
enhanced it.
However, we were still believers and decided to follow another
lead. Zoë had shown that the minimal repeating unit of heparin
that could inhibit RANTES-induced peritoneal recruitment was a
tetrasaccharide.We therefore hired another postdoctoral scientist,
India Severin, a chemist whose objective was to identify and
then synthesize GAG-based mimetics. Despite a very assiduous
program in collaboration with a glycobiology group in Australia,
led by Deidre Coombe, we had to admit defeat. Although we
identified moieties that inhibited GAG binding to RANTES as
well as RANTES binding to the receptor CCR1, we did not achieve
our aim of identifying a lead candidate for an anti-inflammatory
program (12).
To my delight, several years later, Deidre contacted me with
the explanation as to why the design of our dimer resulting
from our screen by NMR was incorrect. We had performed our
crystallization studies at an acidic pH in order to maintain the
monomeric form of RANTES, which would crystallize without
aggregating. Modeling studies at physiological pH values revealed
that our compounds had bound to the protein at acidic pH in a
manner different from that predicted by the docking studies at
physiological pH, presumably due to their different protonation
states (13). And evenmore consolingwas the publication of aGAG
moiety that had anti-inflammatory properties in a model of lung
inflammation by preventing T-cell recruitment (14).
However, we still have a long way to go to fully understand the
inter-relationship between the two interactions that chemokines
have, especially in vivo. Chemokine biologists have always talked
about gradients, but without defining whether these gradients are
in the fluid phase or caused by immobilized chemokines through
their interaction with GAGs. Our work showed that chemokines
needed to be immobilized but did not address the question of
a gradient. This has recently been beautifully demonstrated by
Michael Sixt, where he visualized gradients of CCL21 leading to
lymphatic vessels (15). We believed that the active form of the
chemokinemust be that, which is immobilized on the extracellular
surface. However, our recent work at Novimmune, with Nicolas
Fischer and Marie Kosco-Vilbois and another very talented Ph.D.
student, Pauline Bonvin, characterizing two anti-murine CXCL10
antibodies, has led to revisiting this hypothesis. The mAb that is
active in in vivomodels of disease does not recognize GAG bound
chemokine, whereas the mAb that is ineffective does, a result,
which contradicts the notion that it is the GAG bound form of
the chemokine that is active in vivo (Bonvin et al., manuscript
in preparation). However, the active mAb inhibits the binding
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of the chemokine to GAGs, indicating that this interaction does
indeed play a role, but the point of intervention appears more
subtle that initially thought. Hopefully, more detailed studies of
these two antibodies will provide a greater in depth understanding
of the role of GAG binding in chemokine-induced cell migration
in vivo.
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